Arthneeti
All Q1 FY27 results →
CP

Caplin Point Laboratories Ltd

Q1 FY27Pharmaceuticals & Biotechnology

Caplin Point Laboratories Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management said on revenue, margins and capex.

Price₹2,301
Market cap₹17.5K Cr
P/E26.3
Updated16 Oct 2026
Read4 min read

What the Q1 FY27 call signalled

3 of 5 strong

RevenueGood growth
MarginMargins steady
CapexCapex planned
FundraiseNo fundraise planned
Order bookOrder book rising

The short version

Caplin Point Laboratories anticipates significant growth driven by expansion in sterile manufacturing capacity, oncology, oral solids, dermatology, and API capabilities (Page 11). Revenue grew 20% in Q1 FY27, with robust growth in US (26%) and LatAm markets.

From Caplin Point Laboratories Ltd's Q1 FY27 earnings-call transcript · updated 16 Oct 2026.

Revenue & Sales Performance

Good growth
  • Caplin Point Laboratories anticipates significant growth driven by expansion in sterile manufacturing capacity, oncology, oral solids, dermatology, and API capabilities (Page 11).
  • New sterile lines: Currently 6 lines with plans to operate up to 17 lines by 2029 and beyond, indicating phased capacity ramp-up and higher volumes (Page 13).
  • Expansion into new markets including Mexico, Brazil, Chile, and Central America with plans to set up a factory in Mexico, which offers price advantages (Pages 4, 12).
  • Supplementary tenders in existing markets like El Salvador expected to continue, with repeated incremental orders quarter on quarter (Page 14).

2 more points from Caplin Point Laboratories Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Caplin Point Laboratories Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Building new infrastructure across segments: injectables, tablets, capsules, ointments, all meeting international standards to target regulated global markets.
  • Plans to set up a factory in Mexico (land already purchased), benefiting from a 16% price advantage in tenders.
  • Expanding sterile manufacturing capacity from 5 to 17 lines, including niche areas like blow-fill-seal and inhalation products.
  • Increasing backward integration with API manufacturing for captive consumption.
  • Digitalization initiatives: paperless factories, video masters for institutional memory, AI cameras, and plans for digital twins for remote monitoring.
  • Expansion of Amaris Clinical to support more Bioequivalence (BE) studies.
  • Investment to be funded from internal cash flow; no debt taken.
  • Considering acquisitions such as a distribution company in Mexico to enhance market understanding.

2 more points from Caplin Point Laboratories Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Caplin Point Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Order book rising
  • The original tender mentioned by Mr. Vivek has been completely supplied.
  • Supplementary tenders continue to come in at about 10 to 15% of the original volume.
  • The company has participated in these supplementary tenders and expects decisions in a couple of months.
  • Additional quantities of products already supplied keep coming quarter on quarter.
  • The company is experiencing strong demand, with current capacity booked out till almost February next year.

2 more points from Caplin Point Laboratories Ltd's call on order book

Create a free account to keep reading this call

Caplin Point Laboratories Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹600 Cr, net profit ₹173 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Caplin Point Laboratories Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharma (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjiv.Parant. (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharma.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Caplin Point Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Caplin Point Laboratories Ltd Q1 FY27 results?

Caplin Point Laboratories anticipates significant growth driven by expansion in sterile manufacturing capacity, oncology, oral solids, dermatology, and API capabilities (Page 11). Revenue grew 20% in Q1 FY27, with robust growth in US (26%) and LatAm markets.

What is Caplin Point Laboratories Ltd share price analysis?

Caplin Point Laboratories Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 26.3 with a market cap of ₹17,491 Cr. Investors should review the full earnings analysis for detailed insights.

Is Caplin Point Laboratories Ltd planning capital expenditure?

Building new infrastructure across segments: injectables, tablets, capsules, ointments, all meeting international standards to target regulated global markets.

Keep Caplin Point Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.